Piper Sandler raised the price target for the Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock to “an Overweight”. The rating was released on February 03, 2023, according to finviz. We previously noted in another research note published on November 17, 2022 by Goldman that upgraded the stock from a Sell to a Neutral with a price target of $32 for AGIO stock. The research report from SVB Leerink has upgraded the stock from Mkt Perform to Outperform, with a price target set at $33. The stock was initiated by BofA Securities, who disclosed in a research note on December 03, 2021, to Buy and set the price objective to $54. In their research brief published July 30, 2021, Goldman analysts downgraded the Agios Pharmaceuticals Inc. stock from Neutral to Sell with a price target of $39.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) dipped -3.08% to close Friday’s market session at $23.26, lower as compared to yesterday’s close. The stock price fluctuated between $22.985 and $23.89 throughout the trading session with the volume trading being 796419 shares, which represented a significant variation when compared to the three months average volume of 521.79K shares. The firm’s stock price fluctuated 5.87% within the last five trades and -16.06% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -31.75% in the last 6 months and -25.02% was subtracted to its value over the previous 3 months. AGIO stock is trading at a margin of -5.45%, -15.19% and -12.61% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
As of the close of trading, AGIO deals in the Healthcare domain. The stock is trading -33.08 percent below its 52-week high and 38.87 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -34.04. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Agios Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $1.32 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 93.15 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.16, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Schenkein David P, the Director at Agios Pharmaceuticals Inc. (AGIO) has sold 20,000 shares of firm on Mar 13 at a price of $22.49 against the total amount of $0.45 million. In another inside trade, Washburn Theodore James Jr., Principal Accounting Officer of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) sold 504 shares of the firm on Mar 03 for a total worth of $12242.0 at a price of $24.29. An inside trade which took place on Feb 27, Director of Agios Pharmaceuticals Inc. Schenkein David P sold 20,000 shares of firm against total price of $0.51 million at the cost of $25.37 per share.